NEW YORK (GenomeWeb News) – A variant in a cytochrome P450 enzyme gene called CYP2C19 appears to influence Plavix response and treatment outcomes, according to a genome-wide association study appearing online today in the Journal of the American Medical Association.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.